7.865 USD
+0.12 (+1.48%)
Overall CRMD gets a fundamental rating of 6 out of 10. We evaluated CRMD against 190 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of CRMD get a neutral evaluation. Nothing too spectacular is happening here. CRMD is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make CRMD a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
- CRMD had positive earnings in the past year.
- In the past year CRMD had a positive cash flow from operations.
- CRMD had negative earnings in each of the past 5 years.
- In the past 5 years CRMD always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 21.64%, CRMD belongs to the top of the industry, outperforming 97.89% of the companies in the same industry.
- CRMD's Return On Equity of 43.43% is amongst the best of the industry. CRMD outperforms 97.37% of its industry peers.
- CRMD has a better Return On Invested Capital (13.31%) than 92.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.64% | ||
| ROE | 43.43% | ||
| ROIC | 13.31% |
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of CRMD (75.83%) is better than 98.42% of its industry peers.
- CRMD has a better Operating Margin (48.51%) than 98.95% of its industry peers.
- The Gross Margin of CRMD (92.61%) is better than 94.21% of its industry peers.
- In the last couple of years the Gross Margin of CRMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.51% | ||
| PM (TTM) | 75.83% | ||
| GM | 92.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CRMD is creating some value.
- Compared to 1 year ago, CRMD has more shares outstanding
- Compared to 5 years ago, CRMD has more shares outstanding
- CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 1.56, we must say that CRMD is in the distress zone and has some risk of bankruptcy.
- CRMD has a Altman-Z score of 1.56. This is comparable to the rest of the industry: CRMD outperforms 57.89% of its industry peers.
- CRMD has a debt to FCF ratio of 1.96. This is a very positive value and a sign of high solvency as it would only need 1.96 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 1.96, CRMD belongs to the top of the industry, outperforming 93.68% of the companies in the same industry.
- A Debt/Equity ratio of 0.39 indicates that CRMD is not too dependend on debt financing.
- CRMD has a worse Debt to Equity ratio (0.39) than 60.53% of its industry peers.
- Even though the debt/equity ratio score it not favorable for CRMD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.39 | ||
| Debt/FCF | 1.96 | ||
| Altman-Z | 1.56 |
ROIC/WACC1.42
WACC9.39%
2.3 Liquidity
- CRMD has a Current Ratio of 1.94. This is a normal value and indicates that CRMD is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.94, CRMD is not doing good in the industry: 62.11% of the companies in the same industry are doing better.
- CRMD has a Quick Ratio of 1.73. This is a normal value and indicates that CRMD is financially healthy and should not expect problems in meeting its short term obligations.
- CRMD has a Quick ratio (1.73) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 354.32% over the past year.
- Looking at the last year, CRMD shows a very strong growth in Revenue. The Revenue has grown by 1647.68%.
- CRMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 174.29% yearly.
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
Revenue 1Y (TTM)1647.68%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%
3.2 Future
- The Earnings Per Share is expected to grow by 64.75% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 65.90% on average per year.
EPS Next Y939.09%
EPS Next 2Y178.2%
EPS Next 3Y87.98%
EPS Next 5Y64.75%
Revenue Next Year686.04%
Revenue Next 2Y191.82%
Revenue Next 3Y100.04%
Revenue Next 5Y65.9%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 3.82 indicates a rather cheap valuation of CRMD.
- 96.84% of the companies in the same industry are more expensive than CRMD, based on the Price/Earnings ratio.
- CRMD is valuated cheaply when we compare the Price/Earnings ratio to 28.82, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 4.15 indicates a rather cheap valuation of CRMD.
- 96.84% of the companies in the same industry are more expensive than CRMD, based on the Price/Forward Earnings ratio.
- CRMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.95.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.82 | ||
| Fwd PE | 4.15 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CRMD is valued cheaper than 94.74% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, CRMD is valued cheaper than 93.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.33 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of CRMD may justify a higher PE ratio.
- CRMD's earnings are expected to grow with 87.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y178.2%
EPS Next 3Y87.98%
5. Dividend
5.1 Amount
- CRMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CORMEDIX INC / CRMD FAQ
What is the fundamental rating for CRMD stock?
ChartMill assigns a fundamental rating of 6 / 10 to CRMD.
What is the valuation status for CRMD stock?
ChartMill assigns a valuation rating of 10 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.
Can you provide the profitability details for CORMEDIX INC?
CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.
What is the valuation of CORMEDIX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CORMEDIX INC (CRMD) is 3.82 and the Price/Book (PB) ratio is 1.66.
What is the financial health of CORMEDIX INC (CRMD) stock?
The financial health rating of CORMEDIX INC (CRMD) is 5 / 10.